CLPT trades 150.0% below Wall Street's consensus target of $21.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CLPT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, ClearPoint Neuro, Inc. (CLPT) has a Wall Street consensus price target of $21.50, based on estimates from 3 covering analysts. With the stock currently trading at $8.60, this represents a potential upside of +150.0%. The company has a market capitalization of $258M.
Analyst price targets range from a low of $18.00 to a high of $25.00, representing a 33% spread in expectations. The median target of $21.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CLPT trades at a trailing P/E of -7.4x. Analysts expect EPS to grow +0.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 INVAInnoviva, Inc. | $1.4B | $19.10 | $38.00 | +99.0% | Buy | 7.9x | 11 |
 ABTAbbott Laboratories | $191.5B | $109.93 | $121.36 | +10.4% | Buy | 19.9x | 43 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 ANGOAngioDynamics, Inc. | $485M | $11.73 | $19.00 | +62.0% | Hold | — | 11 |
 ATECAlphatec Holdings, Inc. | $1.1B | $7.44 | $13.60 | +82.8% | Buy | 25.3x | 20 |
 GEGE Aerospace | $335.4B | $323.24 | $385.00 | +19.1% | Buy | 39.6x | 36 |
 GEHCGE HealthCare Technologies Inc. | $37.2B | $82.38 | $81.14 | -1.5% | Buy | 16.4x | 20 |
 SYKStryker Corporation | $124.9B | $325.87 | $354.47 | +8.8% | Buy | 22.0x | 52 |
 ISRGIntuitive Surgical, Inc. | $160.0B | $452.80 | $485.44 | +7.2% | Buy | 40.3x | 57 |
Quick answers to the most common questions about buying CLPT stock.
The consensus Wall Street price target for CLPT is $21.5, representing 150.0% upside from the current price of $8.6. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CLPT has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $21.5 implies 150.0% upside from current levels.
CLPT's current price is $8.6 with a consensus target of $21.5 (150.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $25 for CLPT, while the most conservative target is $18. The consensus of $21.5 represents the median expectation. These targets typically reflect 12-month expectations.
CLPT is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CLPT stock forecast based on 3 Wall Street analysts shows a consensus price target of $21.5, with estimates ranging from $18 (bear case) to $25 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CLPT, with a "Buy" consensus rating and $21.5 price target (150.0% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CLPT analyst price targets range from $18 to $25, a 33% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.